D. R. K. Kakish, J. F. Alsamhori, L. N. Qaqish, et al. “Gender Disparities in Melanoma: Advances in Diagnosis, Treatment, and the Role of Artificial Intelligence,” Dermatologic Therapy 2025; e70022, https://doi.org/10.1002/der2.70022.
In the title of the published article, the phrase “Gender Disparities in Melanoma” should read “Gender and Sex Disparities in Melanoma” to more accurately reflect the scope of the manuscript, which discusses disparities related to both gender identity and biological sex in melanoma diagnosis, treatment, and research.
We apologize for this error.
D. R. K. Kakish， J. F. Alsamhori， L. N. Qaqish，等。“黑色素瘤中的性别差异：诊断、治疗和人工智能的作用的进展”，《皮肤病治疗》2025；e70022, https://doi.org/10.1002/der2.70022.In已发表文章的标题，短语“黑色素瘤中的性别差异”应阅读为“黑色素瘤中的性别和性别差异”，以更准确地反映手稿的范围，该手稿讨论了黑色素瘤诊断、治疗和研究中与性别认同和生理性别相关的差异。我们为这个错误道歉。
{"title":"Correction to “Gender and Sex Disparities in Melanoma: Advances in Diagnosis, Treatment, and the Role of Artificial Intelligence”","authors":"","doi":"10.1002/der2.70034","DOIUrl":"https://doi.org/10.1002/der2.70034","url":null,"abstract":"<p>D. R. K. Kakish, J. F. Alsamhori, L. N. Qaqish, et al. “Gender Disparities in Melanoma: Advances in Diagnosis, Treatment, and the Role of Artificial Intelligence,” <i>Dermatologic Therapy</i> 2025; e70022, https://doi.org/10.1002/der2.70022.</p><p>In the title of the published article, the phrase “Gender Disparities in Melanoma” should read “Gender and Sex Disparities in Melanoma” to more accurately reflect the scope of the manuscript, which discusses disparities related to both gender identity and biological sex in melanoma diagnosis, treatment, and research.</p><p>We apologize for this error.</p>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"6 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144171234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We were presented with a 15-year-old male with Duchenne Muscular Dystrophy and a 5-year history of worsening and treatment-resistant facial erythema.
Methods
To investigate, an H&E punch biopsy was sampled from the left temporal lobe, showing minute vellus-type hairs surrounded by small granulomas and mononuclear cells, including plasma cells.
Results
The findings were most consistent with rosacea, likely the telangiectatic type. Although current research connecting Duchenne Muscular Dystrophy and rosacea is limited, both conditions involve chronic inflammatory states and dysregulation of the immune system, with a notable convergence in NLRP3 inflammasome activation.
Conclusion
Highlighting this connection between DMD and rosacea may pave the way for targeted treatment regimen for both conditions. The similarities in these two disease processes showcase the importance of interdisciplinary communication and research.
{"title":"A Case of Persistent Facial Rash in a 15-Year-Old: Uncovering Rosacea in the Context of Duchenne Muscular Dystrophy","authors":"Kathleen Ward, Valerie Foy, Haowei Han, Sourab Choudhury","doi":"10.1002/der2.70040","DOIUrl":"https://doi.org/10.1002/der2.70040","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>We were presented with a 15-year-old male with Duchenne Muscular Dystrophy and a 5-year history of worsening and treatment-resistant facial erythema.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>To investigate, an H&E punch biopsy was sampled from the left temporal lobe, showing minute vellus-type hairs surrounded by small granulomas and mononuclear cells, including plasma cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The findings were most consistent with rosacea, likely the telangiectatic type. Although current research connecting Duchenne Muscular Dystrophy and rosacea is limited, both conditions involve chronic inflammatory states and dysregulation of the immune system, with a notable convergence in NLRP3 inflammasome activation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Highlighting this connection between DMD and rosacea may pave the way for targeted treatment regimen for both conditions. The similarities in these two disease processes showcase the importance of interdisciplinary communication and research.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"6 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70040","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Skin disorders are highly common in type 1 and 2 diabetes mellitus patients. This study assessed the effects of a moisturizing formulation on photoprotected (volar forearm) and photoexposed (dorsal hand) skin in diabetic and nondiabetic participants, with or without stage I dermatoporosis, comparing it to a reference product.
Methods
Thirty participants, aged 61–81 years, were included and equally divided into diabetic and nondiabetic groups. Biophysical assessments, including capacitance (hydration), transepidermal water loss (TEWL) measurements, and skin micro-imaging for roughness evaluation, were performed at baseline, 45, and 60 days.
Results
The test formulation significantly increased skin hydration, up to 34% on the forearm (FO) and 35% on the dorsal hand (DH) in diabetic participants, and up to 21% on the FO and 27% on the DH in nondiabetic participants. TEWL reduction, indicating improved barrier function, was more pronounced in diabetics (8% on FO and DH), while non-diabetics showed a 1% reduction on the FO. Skin roughness decreased more in diabetics (16% on FO and 18% on DH) than in non-diabetics (11% on DH). Diabetic participants showed greater improvements overall. The test formulation and the reference product demonstrated similar effects in improving skin condition. Participants with stage I dermatoporosis showed significant improvements in skin condition, with the test formulation providing greater benefits for diabetics.
Conclusion
The test formulation effectively enhanced skin hydration and barrier function while reducing skin roughness in diabetic and nondiabetic subjects, regardless of dermatoporosis diagnosis. These findings offer valuable guidance for developing targeted skincare treatments.
{"title":"Moisturizing Treatment Outcomes: A Comparative Study of Diabetic and Nondiabetic Skin, Associated With the Presence or Absence of Dermatoporosis","authors":"Juliana Rodrigues Pinto, Silas Arandas Monteiro e Silva, Gislaine Ricci Leonardi","doi":"10.1002/der2.70037","DOIUrl":"https://doi.org/10.1002/der2.70037","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Skin disorders are highly common in type 1 and 2 diabetes mellitus patients. This study assessed the effects of a moisturizing formulation on photoprotected (volar forearm) and photoexposed (dorsal hand) skin in diabetic and nondiabetic participants, with or without stage I dermatoporosis, comparing it to a reference product.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Thirty participants, aged 61–81 years, were included and equally divided into diabetic and nondiabetic groups. Biophysical assessments, including capacitance (hydration), transepidermal water loss (TEWL) measurements, and skin micro-imaging for roughness evaluation, were performed at baseline, 45, and 60 days.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The test formulation significantly increased skin hydration, up to 34% on the forearm (FO) and 35% on the dorsal hand (DH) in diabetic participants, and up to 21% on the FO and 27% on the DH in nondiabetic participants. TEWL reduction, indicating improved barrier function, was more pronounced in diabetics (8% on FO and DH), while non-diabetics showed a 1% reduction on the FO. Skin roughness decreased more in diabetics (16% on FO and 18% on DH) than in non-diabetics (11% on DH). Diabetic participants showed greater improvements overall. The test formulation and the reference product demonstrated similar effects in improving skin condition. Participants with stage I dermatoporosis showed significant improvements in skin condition, with the test formulation providing greater benefits for diabetics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The test formulation effectively enhanced skin hydration and barrier function while reducing skin roughness in diabetic and nondiabetic subjects, regardless of dermatoporosis diagnosis. These findings offer valuable guidance for developing targeted skincare treatments.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"6 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144100543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daniel L. Fischer, Valerie Foy, Nicole E. Fischer, Graham Litchman, Suzanne Sirota Rozenberg, Adam J. Friedman
Background
Periocular skin is notably thinner than other areas of the body, making it more susceptible to environmental factors and topical medications. Conditions affecting this region often require specialized care due to their impact on quality of life and potential to impair vision.
Aim
This review aims to address the unique characteristics, diagnostic challenges, and therapeutic strategies for oculocutaneous inflammatory conditions, offering guidance for dermatologists in managing this specialized area of skin.
Methods
A literature search was conducted on PubMed reviewing the most relevant periocular inflammatory conditions, including glandular and eyelid inflammation, conjunctival and corneal disorders, allergic and irritant contact dermatitis, autoimmune diseases, and infections. Key diagnostic and therapeutic approaches are highlighted to assist in effective patient management.
Results
Inflammatory oculocutaneous diseases stem from various causes, including eczematous dermatoses, infections, autoimmune conditions, meibomian gland dysfunction. Treatments range from traditional options like warm compresses, antibiotics, and corticosteroids to newer approaches such as biologic therapies and intense pulsed light. These conditions are often associated with allergies, side effects of biologic drugs, and systemic diseases like atopic dermatitis, highlighting the need for accurate diagnosis, personalized treatment, and proper eyelid hygiene for effective management.
Conclusions
Effective management of periocular inflammatory conditions can be challenging due to the unique anatomy of the area and often requires a targeted and specialized approach to treatment. Dermatologists are essential in diagnosing and managing oculocutaneous diseases. Collaboration with optometrists and ophthalmologists is often needed to ensure the best outcomes, as these conditions greatly affect patients’ quality of life and cosmetic appearance.
{"title":"Inflammatory Oculocutaneous Disease: Review, Update, and Practical Approach","authors":"Daniel L. Fischer, Valerie Foy, Nicole E. Fischer, Graham Litchman, Suzanne Sirota Rozenberg, Adam J. Friedman","doi":"10.1002/der2.70036","DOIUrl":"https://doi.org/10.1002/der2.70036","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Periocular skin is notably thinner than other areas of the body, making it more susceptible to environmental factors and topical medications. Conditions affecting this region often require specialized care due to their impact on quality of life and potential to impair vision.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This review aims to address the unique characteristics, diagnostic challenges, and therapeutic strategies for oculocutaneous inflammatory conditions, offering guidance for dermatologists in managing this specialized area of skin.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A literature search was conducted on PubMed reviewing the most relevant periocular inflammatory conditions, including glandular and eyelid inflammation, conjunctival and corneal disorders, allergic and irritant contact dermatitis, autoimmune diseases, and infections. Key diagnostic and therapeutic approaches are highlighted to assist in effective patient management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Inflammatory oculocutaneous diseases stem from various causes, including eczematous dermatoses, infections, autoimmune conditions, meibomian gland dysfunction. Treatments range from traditional options like warm compresses, antibiotics, and corticosteroids to newer approaches such as biologic therapies and intense pulsed light. These conditions are often associated with allergies, side effects of biologic drugs, and systemic diseases like atopic dermatitis, highlighting the need for accurate diagnosis, personalized treatment, and proper eyelid hygiene for effective management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Effective management of periocular inflammatory conditions can be challenging due to the unique anatomy of the area and often requires a targeted and specialized approach to treatment. Dermatologists are essential in diagnosing and managing oculocutaneous diseases. Collaboration with optometrists and ophthalmologists is often needed to ensure the best outcomes, as these conditions greatly affect patients’ quality of life and cosmetic appearance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"6 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144100945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karen Montecinos, Sure Aygun, Margarita S. Lolis, David J. Goldberg
Background
Laser hair removal has been regarded as a relatively safe and effective treatment for the removal of unwanted body hair. While there are a variety of reported side effects like post-inflammatory hyperpigmentation or erythema, a rare and underreported complication is paradoxical hypertrichosis (PH). PH involves the unexpected increase of hair in or near the treatment area following laser hair removal. The mechanism behind this phenomenon is not fully understood but is important to address to improve treatment outcomes and minimize the occurrence of PH.
Objective
This paper aims to consolidate and analyze literature pertaining to PH as a side effect resulting from laser hair removal (LHR), focusing on identifying commonalities and trends.
Materials and Methods
A comprehensive literature search was conducted utilizing the PubMed database, employing keywords such as “laser paradoxical effect” and “paradoxical hypertrichosis.” The gathered findings were synthesized and are presented in this review.
Results
The Alexandrite and Intense Pulsed Light (IPL) lasers are frequently associated with inducing PH. PH predominantly manifests in facial and neck regions, with sporadic occurrences on other body areas, notably the upper arms and periareolar region. Patients with darker skin tones, particularly Fitzpatrick Skin Types III−VI, and those with hormonal imbalances such as polycystic ovarian syndrome (PCOS), are more predisposed to experiencing PH after LHR. Proposed preventive measures include sun protection and avoiding shaving before LHR sessions. Continuation of LHR treatments on affected areas is the standard approach for treating PH.
Conclusion
PH, although rare, poses a tangible side effect of LHR, occurring in about 3% of patients. The literature highlights specific regions of the body and laser types associated with PH, alongside potential patient predispositions. Further research is warranted to elucidate preventive strategies and enhance patient satisfaction and trust in LHR procedures.
{"title":"Trends in Paradoxical Hypertrichosis as a Result of Energy-Based Hair Removal Devices","authors":"Karen Montecinos, Sure Aygun, Margarita S. Lolis, David J. Goldberg","doi":"10.1002/der2.70038","DOIUrl":"https://doi.org/10.1002/der2.70038","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Laser hair removal has been regarded as a relatively safe and effective treatment for the removal of unwanted body hair. While there are a variety of reported side effects like post-inflammatory hyperpigmentation or erythema, a rare and underreported complication is paradoxical hypertrichosis (PH). PH involves the unexpected increase of hair in or near the treatment area following laser hair removal. The mechanism behind this phenomenon is not fully understood but is important to address to improve treatment outcomes and minimize the occurrence of PH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This paper aims to consolidate and analyze literature pertaining to PH as a side effect resulting from laser hair removal (LHR), focusing on identifying commonalities and trends.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A comprehensive literature search was conducted utilizing the PubMed database, employing keywords such as “laser paradoxical effect” and “paradoxical hypertrichosis.” The gathered findings were synthesized and are presented in this review.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The Alexandrite and Intense Pulsed Light (IPL) lasers are frequently associated with inducing PH. PH predominantly manifests in facial and neck regions, with sporadic occurrences on other body areas, notably the upper arms and periareolar region. Patients with darker skin tones, particularly Fitzpatrick Skin Types III−VI, and those with hormonal imbalances such as polycystic ovarian syndrome (PCOS), are more predisposed to experiencing PH after LHR. Proposed preventive measures include sun protection and avoiding shaving before LHR sessions. Continuation of LHR treatments on affected areas is the standard approach for treating PH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>PH, although rare, poses a tangible side effect of LHR, occurring in about 3% of patients. The literature highlights specific regions of the body and laser types associated with PH, alongside potential patient predispositions. Further research is warranted to elucidate preventive strategies and enhance patient satisfaction and trust in LHR procedures.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"6 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144100942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Samar Alyousef, Lama Alqahtani, Asem Shadid, Mohammed Almashali
Background
Lichen sclerosus (LS) is an inflammatory skin disease that predominantly affects the anogenital region, although it can occasionally present in extragenital areas. The precise etiology of LS remains uncertain; however, recent studies suggest that certain medications may contribute to its onset or exacerbate its progression. This systematic review and meta-analysis aims to evaluate the association between specific medications and the development of LS.
Methods
A comprehensive search of multiple databases identified 16 publications that met the inclusion criteria. These studies, primarily comprising case reports and case series, revealed a significant correlation between LS and immune checkpoint inhibitors (ICIs), such as nivolumab and pembrolizumab, as well as hormonal therapies, including anti-androgenic oral contraceptives and aromatase inhibitors.
Results
The findings suggest that these medications may disrupt immune tolerance or hormonal homeostasis, thereby contributing to the pathogenesis of LS. The analysis highlights the challenges in managing medication-induced LS, particularly in patients who cannot discontinue the implicated drug due to underlying conditions such as cancer or chronic illnesses.
Conclusion
Despite offering valuable insights into the potential risks of specific medications, the study's limitations—including reliance on small case studies and data heterogeneity—underscore the need for further research. Larger observational studies and randomized controlled trials are essential to validate these associations and inform targeted prevention and treatment strategies. Clinicians should remain vigilant for signs of LS in patients undergoing treatment with these medications to facilitate early diagnosis and intervention.
{"title":"Medication-Induced Lichen Sclerosus: A Systematic Review","authors":"Samar Alyousef, Lama Alqahtani, Asem Shadid, Mohammed Almashali","doi":"10.1002/der2.70031","DOIUrl":"https://doi.org/10.1002/der2.70031","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lichen sclerosus (LS) is an inflammatory skin disease that predominantly affects the anogenital region, although it can occasionally present in extragenital areas. The precise etiology of LS remains uncertain; however, recent studies suggest that certain medications may contribute to its onset or exacerbate its progression. This systematic review and meta-analysis aims to evaluate the association between specific medications and the development of LS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A comprehensive search of multiple databases identified 16 publications that met the inclusion criteria. These studies, primarily comprising case reports and case series, revealed a significant correlation between LS and immune checkpoint inhibitors (ICIs), such as nivolumab and pembrolizumab, as well as hormonal therapies, including anti-androgenic oral contraceptives and aromatase inhibitors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The findings suggest that these medications may disrupt immune tolerance or hormonal homeostasis, thereby contributing to the pathogenesis of LS. The analysis highlights the challenges in managing medication-induced LS, particularly in patients who cannot discontinue the implicated drug due to underlying conditions such as cancer or chronic illnesses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Despite offering valuable insights into the potential risks of specific medications, the study's limitations—including reliance on small case studies and data heterogeneity—underscore the need for further research. Larger observational studies and randomized controlled trials are essential to validate these associations and inform targeted prevention and treatment strategies. Clinicians should remain vigilant for signs of LS in patients undergoing treatment with these medications to facilitate early diagnosis and intervention.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"6 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70031","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143840893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Valentina Dicker, Luis Alberto Parra, Andreina Martinez Amado, Andrea Acevedo, Desiree Castelanich, Lina Velasquez, Andrea Marcela Parra
Background
Nonsurgical skin tightening using high-intensity focused ultrasound (HIFU) and micro focused ultrasound (MFU) is a rapidly growing aesthetic procedure. However, a lack of comparative data on the technical specifications of leading devices (Ultherapy, Ultraformer, Liftera) hinders optimal treatment selection. This review addresses this gap.
Materials and Methods
For each device, a literature search (PubMed, Google Scholar, grey literature) focused on skin-tightening applications. Inclusion criteria included articles published in English or Spanish after 2017 detailing technical specifications. Data extraction included regulatory approvals, ultrasound frequency, energy levels, treatment depths, thermal coagulation points per shot, and other treatment parameters.
Results
The review analyzed data from available publications and manufacturer documentation. Significant heterogeneity was identified across devices regarding ultrasound frequency, energy levels, treatment depths, and real-time visualization capabilities. Ultherapy uniquely offers real-time imaging. Due to limited published research, Ultraformer and Liftera data relied heavily on manufacturer information.
Conclusion
This literature review reveals substantial heterogeneity in the technical specifications of Ultherapy, Ultraformer, and Liftera for nonsurgical skin tightening. The lack of published literature for Ultraformer and Liftera highlights the need for further research to confirm manufacturer-provided specifications and to establish clear evidence-based guidelines for optimal treatment selection. The value of real-time imaging in treatment optimization is also discussed.
{"title":"High-Intensity Focused Ultrasound Devices for Skin Tightening: A Comparative Literature Review of Device Specifications","authors":"Valentina Dicker, Luis Alberto Parra, Andreina Martinez Amado, Andrea Acevedo, Desiree Castelanich, Lina Velasquez, Andrea Marcela Parra","doi":"10.1002/der2.70030","DOIUrl":"https://doi.org/10.1002/der2.70030","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Nonsurgical skin tightening using high-intensity focused ultrasound (HIFU) and micro focused ultrasound (MFU) is a rapidly growing aesthetic procedure. However, a lack of comparative data on the technical specifications of leading devices (Ultherapy, Ultraformer, Liftera) hinders optimal treatment selection. This review addresses this gap.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>For each device, a literature search (PubMed, Google Scholar, grey literature) focused on skin-tightening applications. Inclusion criteria included articles published in English or Spanish after 2017 detailing technical specifications. Data extraction included regulatory approvals, ultrasound frequency, energy levels, treatment depths, thermal coagulation points per shot, and other treatment parameters.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The review analyzed data from available publications and manufacturer documentation. Significant heterogeneity was identified across devices regarding ultrasound frequency, energy levels, treatment depths, and real-time visualization capabilities. Ultherapy uniquely offers real-time imaging. Due to limited published research, Ultraformer and Liftera data relied heavily on manufacturer information.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This literature review reveals substantial heterogeneity in the technical specifications of Ultherapy, Ultraformer, and Liftera for nonsurgical skin tightening. The lack of published literature for Ultraformer and Liftera highlights the need for further research to confirm manufacturer-provided specifications and to establish clear evidence-based guidelines for optimal treatment selection. The value of real-time imaging in treatment optimization is also discussed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"6 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70030","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号